DALE SUMILANG: Open Payments
NPI 1154938744 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,047 in 37 payments from 10 companies in 2025. Trend: 2023 $3,673 · 2024 $3,615 · 2025 $1,047
Food & beverage: $1,047
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $378 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $167 |
| Janssen Biotech, Inc. | 8 | $148 |
| Gilead Sciences, Inc. | 3 | $87 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| Celltrion USA Inc. | 3 | $74 |
| QOL Medical, LLC | 1 | $33 |
| Intercept Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $25 |
Products named: ENTYVIO, SKYRIZI, TREMFYA, CREON, RINVOQ, XIFAXAN, VEGZELMA, Sucraid.
Industry payments across RI — which companies pay providers there.
